Welcome to our dedicated page for Olaplex Holdings SEC filings (Ticker: OLPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olaplex Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed beauty company with common stock registered under the symbol OLPX. Recent Form 8-K reports cover results of operations and financial condition, including sales performance across professional, specialty retail, and direct-to-consumer channels and U.S. and international markets.
The filing record also documents material definitive agreements, capital-structure disclosures, shareholder voting matters, governance changes, and compensatory arrangements. Company-specific disclosures include the completed acquisition of Purvala Bioscience by an Olaplex subsidiary, board composition updates, and other material-event reporting tied to the company’s hair-care innovation and public-company obligations.
Olaplex Holdings, Inc. is asking stockholders to vote at its 2026 Annual Meeting, to be held virtually on July 9, 2026 at 11:00 a.m. Eastern Time. Investors will be asked to elect four Class II directors for three-year terms, approve on an advisory basis executive pay for fiscal 2025, and ratify Deloitte & Touche LLP as independent auditor for fiscal 2026.
The proxy details Olaplex’s classified board, committee structure and “controlled company” status under Nasdaq rules, with Advent funds holding about 74% of common stock as of May 12, 2026. It also describes director compensation, equity awards, stock ownership guidelines, clawback policies, and the company’s focus on diversity, inclusion and environmental sustainability.
Olaplex Holdings, Inc. is moving toward resolving stockholder derivative litigation through a proposed settlement that has received preliminary court approval. The case involves derivative actions and a books-and-records demand related to issues similar to a prior securities class action against the company.
Under the proposed settlement, Olaplex will adopt specified corporate governance reforms and defendants’ insurers will pay $700,000 in attorneys’ fees and expenses, subject to court approval. The settlement, which would release all related derivative claims, is subject to final approval at a Settlement Hearing scheduled for July 27, 2026.
OLAPLEX HOLDINGS, INC. Chief People Officer Trisha L. Fox reported an open-market sale of 16,324 shares of common stock at $2.04 per share. According to the filing, this "sell to cover" transaction was required to satisfy tax withholding obligations from vesting restricted stock units. After the sale, she continues to directly hold 1,064,039 shares, indicating the transaction was a small, tax-driven adjustment rather than a change in her overall equity position.
Olaplex Holdings, Inc. reported a Q1 2026 net loss while advancing a proposed cash acquisition by Henkel US Operations Corporation at $2.06 per share.
Net sales rose to $99.4 million, up 2.5% year over year, as professional channel revenue grew 12.3% and DTC 13.8%, partly offset by a 13.3% decline in specialty retail. Gross margin improved to 72.1% from 69.5% due to mix and lower inventory write-offs.
Higher selling, general and administrative expenses of $66.0 million, driven by $7.4 million of merger-related costs, increased marketing and higher payroll, led to a net loss of $5.3 million versus a small profit a year earlier. The company ended the quarter with $326.2 million in cash, $354.8 million of term loan debt and total available liquidity of about $525 million including its undrawn revolver. The Henkel merger faces customary regulatory and closing conditions, an outside completion date of March 31, 2027 (extendable to September 30, 2027), and includes a potential $40.44 million termination fee and amendments to Olaplex’s Tax Receivable Agreement.
Olaplex Holdings reported first quarter 2026 results and reiterated its pending all-cash sale to Henkel for $2.06 per share, valuing the company at about $1.4 billion.
Net sales rose 2.5% to $99.4 million, driven by double-digit growth in Professional and Direct-to-Consumer channels, while Specialty Retail declined 13.3%. Net results swung to a net loss of $5.3 million from net income of $0.5 million, with diluted EPS at $(0.01). Adjusted EBITDA fell to $19.0 million with margin of 19.1%, down from 26.5%.
Olaplex ended the quarter with cash and cash equivalents of $326.2 million and long-term debt of $352.5 million. Given the Henkel transaction, the company will not host a conference call or provide updated financial guidance.
Olaplex Holdings, Inc. entered into an Agreement and Plan of Merger dated March 26, 2026 under which Merger Sub will merge into the company and each outstanding share of common stock will be converted into the right to receive $2.06 per share in cash (the Merger Consideration). A group of controlling stockholders (the Advent Stockholders) holding an aggregate of 499,468,771 Shares delivered a written consent adopting the Merger Agreement, satisfying the required stockholder approval and eliminating the need for a stockholder meeting. Holders who comply with Delaware appraisal procedures under Section 262 may seek a judicial determination of the fair value of their shares instead of accepting the Merger Consideration. The Parties expect regulatory clearances under U.S. and other antitrust laws to be required before closing.
Olaplex Holdings, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add detailed disclosures on directors, corporate governance and 2025 executive compensation. The filing shows non-affiliate voting stock market value of $198.1 million as of June 30, 2025 and 672,042,176 shares outstanding as of April 20, 2026.
Olaplex describes its status as a Nasdaq “controlled company,” related committee exemptions, and an Information Security Subcommittee focused on cybersecurity and artificial intelligence. The Compensation Discussion and Analysis outlines 2025 net sales of $423 million and adjusted EBITDA of $94 million, producing annual bonuses at 103% of target for named executives, alongside large time-vested RSU grants and robust stock ownership, anti-hedging and clawback policies.
Olaplex Holdings, Inc. is being acquired by Henkel US Operations Corporation through a merger under the Agreement and Plan of Merger dated March 26, 2026. At the Effective Time, each outstanding share of Common Stock (other than treasury, Parent-held shares and valid Dissenting Shares) will be converted into the right to receive $2.06 per share in cash. The Board unanimously approved and recommended the Merger and J.P. Morgan delivered a fairness opinion that the Merger Consideration is fair, from a financial point of view. Principal holders affiliated with Advent delivered a written consent representing an aggregate 499,468,771 shares (approximately 75%), satisfying the required stockholder approval; no stockholder meeting will be held. The Merger is subject to customary closing conditions, regulatory clearances and certain procedures for receiving cash consideration; appraisal rights under Section 262 of the DGCL are available to eligible holders.
Olaplex Holdings, Inc. General Counsel John C. Duffy reported an open-market sale of 11,471 shares of common stock at $2.02 per share. According to the footnote, this was a required “sell to cover” transaction to satisfy tax withholding on vested restricted stock units.
After the sale, Duffy directly owned 971,384 shares of Olaplex common stock. Because the sale was driven by tax obligations tied to RSU vesting rather than a discretionary trade, it reflects a routine compensation-related activity rather than a change in investment stance.
Olaplex Holdings, Inc. has agreed to be acquired by Henkel in an all-cash merger. Henkel will pay $2.06 per share, valuing Olaplex at approximately $1.4 billion, a premium of about 55% to the prior closing price and 45% to the 30-day VWAP.
Merger Sub will merge into Olaplex, which will become a wholly owned Henkel subsidiary and be delisted from Nasdaq. Advent-affiliated funds holding roughly 75% of shares approved the deal by written consent. Closing is subject to antitrust and other regulatory clearances and customary conditions, with an outside date that can extend to September 30, 2027. A $40.44 million termination fee may be payable by Olaplex to Henkel in specified scenarios.